Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 48.59 | -2.27% | -1.13 |
Earnings due: Jul 28
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical AGIO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -2.27% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 200 DMA Support | about 9 hours ago |
| 1.5x Volume Pace | about 13 hours ago |
| Down 3% | about 13 hours ago |
| Down 2 % | about 13 hours ago |
| Down 1% | about 13 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 07/28/2021
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Cancers Hydrogen Metabolism Organic Chemistry Inborn Errors Of Metabolism Glutamate Agios Pharmaceuticals Glutaminase Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 62.155 |
| 52 Week Low | 32.47 |
| Average Volume | 691,169 |
| 200-Day Moving Average | 49.26 |
| 50-Day Moving Average | 56.47 |
| 20-Day Moving Average | 54.98 |
| 10-Day Moving Average | 53.62 |
| Average True Range | 1.95 |
| ADX | 18.81 |
| +DI | 12.50 |
| -DI | 39.63 |
| Chandelier Exit (Long, 3 ATRs) | 52.73 |
| Chandelier Exit (Short, 3 ATRs) | 53.70 |
| Upper Bollinger Bands | 60.43 |
| Lower Bollinger Band | 49.53 |
| Percent B (%b) | -0.09 |
| BandWidth | 19.83 |
| MACD Line | -1.69 |
| MACD Signal Line | -0.83 |
| MACD Histogram | -0.8611 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 52.19 | ||||
| Resistance 3 (R3) | 52.35 | 51.30 | 51.59 | ||
| Resistance 2 (R2) | 51.30 | 50.39 | 51.23 | 51.39 | |
| Resistance 1 (R1) | 49.95 | 49.82 | 49.43 | 49.79 | 51.19 |
| Pivot Point | 48.90 | 48.90 | 48.64 | 48.83 | 48.90 |
| Support 1 (S1) | 47.55 | 47.99 | 47.03 | 47.39 | 45.99 |
| Support 2 (S2) | 46.50 | 47.42 | 46.43 | 45.79 | |
| Support 3 (S3) | 45.15 | 46.50 | 45.59 | ||
| Support 4 (S4) | 44.99 |
